Edit Entry

Mark R. Spaller, Ph.D.

Title(s):
Associate Professor of Pharmacology & Toxicology

Department(s):
Pharmacology & Toxicology

Programs:
Norris Cotton Cancer Center
Pharmacology and Toxicology Graduate Program
Program in Experimental and Molecular Medicine

Websites:
http://dms.dartmouth.edu/spaller/

Contact Information:

7936 Rubin 652
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon NH 03756

Office: Rubin 652
Phone: 653-6197
Fax: 653-9952
Email: mspaller@dartmouth.edu


Professional Interests:

Discovery and development of cellular probes and therapeutic agents targeting protein-protein interactions; chemical biology; peptide and organic small molecule design and synthesis; bacteriophage and phage display; chemical libraries for biochemical and cell-based screening; protein biochemistry and biophysical analysis of protein-ligand interactions.

Rotations and Thesis Projects:

Rotation and thesis projects are available that correspond to the topics listed above under “Professional Interests”. These are applicable to the study of diseases involving cancer, neurobiological disorders, and bacterial infection.


Selected Publications:

 

  • Saro D, Li T, Rupasinghe C, Paredes A, Caspers N, Spaller MR. A thermodynamic ligand binding study of the third PDZ domain (PDZ3) from the mammalian neuronal protein PSD-95. Biochemistry. 2007 May 29;46(21):6340-52. (view details on MedLine)

  • Sharma SC, Rupasinghe CN, Parisien RB, Spaller MR. Design, synthesis, and evaluation of linear and cyclic peptide ligands for PDZ10 of the multi-PDZ domain protein MUPP1. Biochemistry. 2007 Nov 6;46(44):12709-20. (view details on MedLine)

  • Udugamasooriya DG, Spaller MR. Conformational constraint in protein ligand design and the inconsistency of binding entropy. Biopolymers. 2008 Aug;89(8):653-67. (view details on MedLine)

  • Udugamasooriya DG, Sharma SC, Spaller MR. A chemical library approach to organic-modified peptide ligands for PDZ domain proteins: a synthetic, thermodynamic and structural investigation. Chembiochem. 2008 Jul 2;9(10):1587-9. (view details on MedLine)

  • Memic A, Spaller MR. How do halogen substituents contribute to protein-binding interactions? A thermodynamic study of peptide ligands with diverse aryl halides. Chembiochem. 2008 Nov 24;9(17):2793-5. (view details on MedLine)

  • Sharma SC, Memic A, Rupasinghe CN, Duc AC, Spaller MR. T7 phage display as a method of peptide ligand discovery for PDZ domain proteins. Biopolymers. 2009;92(3):183-93. (view details on MedLine)

  • Muders MH, Vohra PK, Dutta SK, Wang E, Ikeda Y, Wang L, Udugamasooriya DG, Memic A, Rupasinghe CN, Baretton GB, Aust DE, Langer S, Datta K, Simons M, Spaller MR, Mukhopadhyay D. Targeting GIPC/synectin in pancreatic cancer inhibits tumor growth. Clin Cancer Res. 2009 Jun 15;15(12):4095-103. (view details on MedLine)

  • LeBlanc BW, Iwata M, Mallon AP, Rupasinghe CN, Goebel DJ, Marshall J, Spaller MR, Saab CY. A cyclic peptide targeted against PSD-95 blocks central sensitization and attenuates thermal hyperalgesia. Neuroscience. 2010 May 5;167(2):490-500. (view details on MedLine)

  • Wang L, Lau JS, Patra CR, Cao Y, Bhattacharya S, Dutta S, Nandy D, Wang E, Rupasinghe CN, Vohra P, Spaller MR, Mukhopadhyay D. RGS-GAIP-interacting protein controls breast cancer progression. Mol Cancer Res. 2010 Dec;8(12):1591-600. (view details on MedLine)

  • Patra CR, Rupasinghe CN, Dutta SK, Bhattacharya S, Wang E, Spaller MR, Mukhopadhyay D. Chemically modified peptides targeting the PDZ domain of GIPC as a therapeutic approach for cancer. ACS Chem Biol. 2012 Apr 20;7(4):770-9. (view details on MedLine)